Tag: TSXV:ACST

November 26, 2019

Acasti Pharma Updates on TRILOGY 1 Phase 3 Trial

The company announced that the last patient completed their final visit in its TRILOGY 1 pivotal Phase 3 clinical trial...
November 18, 2019

Acasti Pharma Releases Preliminary Data for CaPre in Diabetic Mice

According to the announcement, CaPre demonstrated insulin secretion, which its counterpart metformin is not able to do.
September 30, 2019

Acasti Pharma Releases Additional Phase 3 Milestones

The company said that almost 80 percent of the patients in the Phase 3 TRILOGY trial have completed randomization in...
September 9, 2019

Acasti Pharma Receives Funding from the Government of Canada

Acasti Pharma (NASDAQ:ACST, TSXV:ACST) has announced the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) has awarded it...
December 31, 2018

Acasti Pharma Announces Data on TRILOGY Phase 3 Trials of CaPre in Patients

Acasti Pharma (NASDAQ:ACST;TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre (omega-3...
November 14, 2018

Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019

Acasti Pharma (NASDAQ:ACST,TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid)...
October 4, 2018

Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares

Acasti Pharma (NASDAQ:ACST;TSXV:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre (omega-3...